Sign Up
Stories
Innovative GI Drug Data Revealed
Share
4D Molecular Therapeutics Raises $300 Mi...
4DMT Presents Positive Interim Data
89bio to Present pegozafermin for NASH a...
AGO Recognition Boosts BluePrint® Impact
ANJESO Drug Insight and Market Forecast
Advancing OSE-279: Promising Cancer Trea...
Overview
API
Ironwood Pharmaceuticals to present new data on apraglutide for SBS-IF at DDW 2024, aiming for FDA NDA submission. The company will also highlight linaclotide data, strengthening its GI treatment market presence.
Ask a question
How might the new data on apraglutide impact the treatment landscape for Short Bowel Syndrome with Intestinal Failure?
In what ways could Ironwood's strategic moves influence the pharmaceutical industry's approach to GI treatments?
What competitive advantages does Ironwood gain by showcasing linaclotide data for IBS-C and FC?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Feb 2024
Mar 2024
Apr 2024
Coverage